Department of Basic Pathology, National Defense Medical College, Ohki Memorial Kikuchi Cancer Clinic for Women, Tokorozawa, Saitama, Japan.
Int J Gynecol Pathol. 2011 Mar;30(2):129-38. doi: 10.1097/PGP.0b013e3181f71264.
Pathologic slides from 150 patients with clear cell adenocarcinoma from the collaborating institutions were reviewed independently by 2 pathologists, and each tumor was graded histologically using the Shimizu-Silverberg and International Federation of Gynecology and Obstetrics (FIGO) grading systems. For the Shimizu-Silverberg grading system, 3 parameters-architectural pattern, nuclear pleomorphism, and mitotic activity-were assessed and scored as 1 to 3. When the summed scores of these parameters were 3 to 5, 6 to 7, and 8 to 9, grades 1, 2, and 3 were assigned, respectively. The FIGO grade was based on the ratio of glandular/papillary growth versus solid growth: grade 1, less than 5% solid tumor; grade 2, 5% to 50% solid tumor; grade 3, greater than 50% solid tumor. Interobserver agreement levels for assignment of both gradings were fair (κ=0.32 and 0.24, respectively). After consensus had been acquired, 82 (55%), 56 (37%), and 12 (8%) tumors were classified as grades 1, 2, and 3 by the Shimizu-Silverberg grading system, and 88 (59%), 38 (25%), and 24 (16%) were classified as grades 1, 2, and 3 by the FIGO grading system, respectively. Survival analyses indicated that patients with grade 3 tumors, as defined by both the grading systems, tended to have a poor outcome, but any differences between them were not statistically significant. Multivariate analysis showed that only the presence of residual tumor after initial surgery was an independent prognostic factor for overall survival. These results suggest that the 2 tested grading systems have limited value for the prognostication of patients with clear cell adenocarcinoma, and that a more effective grading system for this tumor may be required.
150 例来自合作机构的透明细胞腺癌患者的病理切片由 2 位病理学家独立进行回顾,每个肿瘤均采用 Shimizu-Silverberg 和国际妇产科联盟(FIGO)分级系统进行组织学分级。对于 Shimizu-Silverberg 分级系统,评估了 3 个参数-结构模式、核异型性和有丝分裂活性,并分别评分为 1 到 3。当这些参数的总和评分为 3 到 5、6 到 7 和 8 到 9 时,分别分配等级 1、2 和 3。FIGO 分级基于腺体/乳头生长与实性生长的比例:1 级,小于 5%的实性肿瘤;2 级,5%至 50%的实性肿瘤;3 级,大于 50%的实性肿瘤。两种分级的分配的观察者间一致性水平为中等(κ 值分别为 0.32 和 0.24)。在达成共识后,82 例(55%)、56 例(37%)和 12 例(8%)肿瘤分别根据 Shimizu-Silverberg 分级系统被归类为 1、2 和 3 级,而 88 例(59%)、38 例(25%)和 24 例(16%)分别根据 FIGO 分级系统被归类为 1、2 和 3 级。生存分析表明,两种分级系统定义的 3 级肿瘤患者预后较差,但两者之间的差异无统计学意义。多变量分析显示,仅初始手术后残留肿瘤的存在是总生存的独立预后因素。这些结果表明,这两种测试的分级系统对预测透明细胞腺癌患者的预后价值有限,可能需要更有效的分级系统。